Literature DB >> 20554644

Toll-like receptor 2 mediates inhibition of HCO(3)(-) absorption by bacterial lipoprotein in medullary thick ascending limb.

David W Good1, Thampi George, Bruns A Watts.   

Abstract

Bacterial infection and sepsis are associated with renal tubule dysfunction and dysregulation of systemic electrolyte balance but the underlying mechanisms are incompletely understood. Recently, we demonstrated that HCO(3)(-) absorption by the medullary thick ascending limb (MTAL) is inhibited by gram-negative bacterial LPS through activation of Toll-like receptor 4 (TLR4). Here, we examined whether MTAL transport is altered by activation of TLR2, the receptor predominantly responsible for recognizing gram-positive bacteria. Confocal immunofluorescence showed expression of TLR2 in the basolateral membrane domain of rat and mouse MTALs. The functional role of TLR2 was examined in perfused MTALs using Pam(3)CSK(4), a bacterial lipoprotein analog that specifically activates TLR2. Adding Pam(3)CSK(4) to the bath decreased HCO(3)(-) absorption by 25%. The inhibition by Pam(3)CSK(4) was eliminated in MTALs from TLR2(-/-) mice. HCO(3)(-) absorption was also inhibited by the TLR2 agonists lipoteichoic acid and peptidoglycan, two cell wall components of gram-positive bacteria. The MEK/ERK inhibitor U0126 eliminated inhibition of HCO(3)(-) absorption by bath LPS but had no effect on inhibition by Pam(3)CSK(4). The inhibition by Pam(3)CSK(4) was eliminated by the protein kinase C inhibitors chelerythrine Cl and bisindolylmaleimide. Moreover, the inhibition by Pam(3)CSK(4), lipoteichoic acid, and peptidoglycan was additive to inhibition by LPS. Thus, agonists of basolateral TLR2 and TLR4 inhibit HCO(3)(-) absorption independently through distinct signaling pathways. We conclude that bacterial components act directly through TLRs to modify the transport function of renal tubules. During polymicrobial sepsis, gram-positive bacterial molecules acting through TLR2 and gram-negative LPS acting through TLR4 can function through parallel signaling pathways to impair MTAL transport. The inhibition of luminal acidification may impair the ability of the kidneys to correct systemic acidosis that contributes to sepsis pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554644      PMCID: PMC2944297          DOI: 10.1152/ajprenal.00108.2010

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  87 in total

1.  Pathophysiology of tissue acidosis in septic shock: blocked microcirculation or impaired cellular respiration?

Authors:  Katja Baumgart; Peter Radermacher; Enrico Calzia; Balázs Hauser
Journal:  Crit Care Med       Date:  2008-02       Impact factor: 7.598

2.  Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney.

Authors:  Jaklien C Leemans; Geurt Stokman; Nike Claessen; Kasper M Rouschop; Gwendoline J D Teske; Carsten J Kirschning; Shizuo Akira; Tom van der Poll; Jan J Weening; Sandrine Florquin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

3.  Toll-like receptor-4: renal cells and bone marrow cells signal for neutrophil recruitment during pyelonephritis.

Authors:  Prashant S Patole; Sören Schubert; Kirsten Hildinger; Sascha Khandoga; Andrej Khandoga; Stephan Segerer; Anna Henger; Matthias Kretzler; Melanie Werner; Fritz Krombach; Detlef Schlöndorff; Hans-Joachim Anders
Journal:  Kidney Int       Date:  2005-12       Impact factor: 10.612

4.  Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy.

Authors:  J Gómez; E García-Vázquez; R Baños; M Canteras; J Ruiz; V Baños; J A Herrero; M Valdés
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

5.  TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways.

Authors:  Alana A Shigeoka; Todd D Holscher; Andrew J King; Frank W Hall; William B Kiosses; Peter S Tobias; Nigel Mackman; Dianne B McKay
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

6.  The scaffold MyD88 acts to couple protein kinase Cepsilon to Toll-like receptors.

Authors:  Amir Faisal; Adrian Saurin; Bernard Gregory; Brian Foxwell; Peter J Parker
Journal:  J Biol Chem       Date:  2008-05-05       Impact factor: 5.157

7.  Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study.

Authors:  Michael Oppert; Christoph Engel; Frank-Martin Brunkhorst; Holger Bogatsch; Konrad Reinhart; Ulrich Frei; Kai-Uwe Eckardt; Markus Loeffler; Stefan John
Journal:  Nephrol Dial Transplant       Date:  2007-12-07       Impact factor: 5.992

8.  Influence of angiotensin II on expression of toll-like receptor 2 and maturation of dendritic cells in chronic cyclosporine nephropathy.

Authors:  Kyung Ohk Ahn; Sun Woo Lim; Can Li; Hyun Joo Yang; Jung Yeon Ghee; Jin Young Kim; Su Hyun Kim; Jin Kim; Chul Woo Yang
Journal:  Transplantation       Date:  2007-04-15       Impact factor: 4.939

9.  Role of AQP1 in endotoxemia-induced acute kidney injury.

Authors:  Weidong Wang; Chunling Li; Sandra N Summer; Sandor Falk; Wei Wang; Danica Ljubanovic; Robert W Schrier
Journal:  Am J Physiol Renal Physiol       Date:  2008-04-23

10.  Toll-like receptor 2 and renal allograft function.

Authors:  Kirsten de Groot; Katharina Kuklik; Verena Bröcker; Anke Schwarz; Wilfried Gwinner; Hans Kreipe; Hermann Haller; Danilo Fliser; Michael Mengel
Journal:  Am J Nephrol       Date:  2008-02-08       Impact factor: 3.754

View more
  13 in total

1.  Basolateral LPS inhibits NHE3 and HCOFormula absorption through TLR4/MyD88-dependent ERK activation in medullary thick ascending limb.

Authors:  Bruns A Watts; Thampi George; Edward R Sherwood; David W Good
Journal:  Am J Physiol Cell Physiol       Date:  2011-08-31       Impact factor: 4.249

Review 2.  Molecular mechanisms and regulation of urinary acidification.

Authors:  Ira Kurtz
Journal:  Compr Physiol       Date:  2014-10       Impact factor: 9.090

3.  High-mobility group box 1 inhibits HCO(3)(-) absorption in medullary thick ascending limb through a basolateral receptor for advanced glycation end products pathway.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  Am J Physiol Renal Physiol       Date:  2015-07-15

4.  Toll-like receptor 2 is required for LPS-induced Toll-like receptor 4 signaling and inhibition of ion transport in renal thick ascending limb.

Authors:  David W Good; Thampi George; Bruns A Watts
Journal:  J Biol Chem       Date:  2012-04-20       Impact factor: 5.157

5.  A two-hit mechanism for sepsis-induced impairment of renal tubule function.

Authors:  Bruns A Watts; Thampi George; Edward R Sherwood; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-16

Review 6.  The Role of Endotoxin in the Setting of Cardiorenal Syndrome Type 5.

Authors:  Anna Clementi; Grazia Maria Virzì; Alessandra Brocca; Claudio Ronco
Journal:  Cardiorenal Med       Date:  2017-06-24       Impact factor: 2.041

Review 7.  Pattern recognition receptors and the inflammasome in kidney disease.

Authors:  Jaklien C Leemans; Lotte Kors; Hans-Joachim Anders; Sandrine Florquin
Journal:  Nat Rev Nephrol       Date:  2014-06-03       Impact factor: 28.314

8.  Lumen LPS inhibits HCO3(-) absorption in the medullary thick ascending limb through TLR4-PI3K-Akt-mTOR-dependent inhibition of basolateral Na+/H+ exchange.

Authors:  Bruns A Watts; Thampi George; David W Good
Journal:  Am J Physiol Renal Physiol       Date:  2013-05-22

Review 9.  Epithelial transport during septic acute kidney injury.

Authors:  Eric D Morrell; John A Kellum; Kenneth R Hallows; Núria M Pastor-Soler
Journal:  Nephrol Dial Transplant       Date:  2013-12-29       Impact factor: 5.992

Review 10.  Acute kidney injury: what part do toll-like receptors play?

Authors:  Patricia G Vallés; Andrea Gil Lorenzo; Victoria Bocanegra; Roberto Vallés
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.